Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vinflunine - Pierre Fabre

Drug Profile

Vinflunine - Pierre Fabre

Alternative Names: F-12158; Javlor; L-0070; Vinflunine ditartrate

Latest Information Update: 01 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pierre Fabre
  • Class Antineoplastics; Vinca alkaloids
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bladder cancer
  • Preregistration Breast cancer
  • Phase III Head and neck cancer; Urogenital cancer
  • No development reported Mesothelioma; Non-small cell lung cancer; Solid tumours
  • Discontinued Gastric cancer; Ovarian cancer

Most Recent Events

  • 28 Mar 2019 Registered for Bladder cancer (Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Chile (IV)
  • 23 Nov 2018 Pierre Fabre Medicament completes a phase III trial in Head and neck cancer (Combination therapy, Locally recurrent, Metastatic disease, Second-line therapy or greater) in Austria, Belgium, Estonia, Germany, Poland, Slovakia, Spain, France and Italy (IV) (NCT02347332) (EudraCT2011-005081-38)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top